At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 33 enrolled
Drug / intervention
seromycin +1 moredrug
Likely dose
Seromycin 100 mg orally 1 hour prior to each therapy sessionAI-extracted
Key inclusion· 3
- ✓Confirmed OCD diagnosis by structured clinical interview
- ✓Yale-Brown Obsessive Compulsive Scale score >16
- ✓Negative pregnancy test at baseline
Key exclusion· 10
- ✕Unstable dose of psychotropic medications within 2 months prior to enrollment
- ✕Medications that may interfere with study drug
- ✕History of seizure disorder or serious medical illness (cardiovascular, liver, kidney, respiratory, endocrine, neurologic, or blood disease)
- ✕Current tuberculosis diagnosis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy
In Brief
A Phase 3 clinical trial evaluating seromycin and Behavior Therapy for Obsessive-Compulsive Disorder. Completed, enrolled 33 participants.
Detailed Summary
This study will assess the effectiveness of Seromycin (D-cycloserine) in enhancing the positive effects of behavior therapy for people with Obsessive-Compulsive Disorder (OCD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder
Countries--
CollaboratorsHartford Hospital
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2003
First PostedSep 2005
Primary CompletionJan 2008
TodayJul 2026
First PostedSep 16, 2005
Enrollment StartNov 1, 2003
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 20.8 years ago
Interventions
seromycindrug
100mg tablet administered 1 hour prior to each therapy session
Behavior Therapybehavioral
10 weekly hour-long behavior therapy sessions